See this manuscript from our friends at Tor Vergata, Roma.
If high protease levels are associated with (expensive) biologic graft failure, then why are we not pairing diagnostics/theragnostics that identify this problem (or others)with these expensive products?
How can we have “wound management” without “wound measurement”? Until this happens, we are collectively flying blind.
Int J Low Extrem Wounds. 2014 Sep;13(3):191-6. doi: 10.1177/1534734614544959. Epub 2014 Aug 8.